
Mark D Pagel, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
About Dr. Pagel
Present Title & Affiliation
Primary Appointment
Dallas Fort Worth Living Legend Professorship, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Department Chair, Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Graduate Faculty, Division of Graduate School of Biomedical Sciences, The University of Texas Health Science Center Houston, Houston, TX
Adjunct Professor, Department of Chemistry, Rice University, Houston, TX
Research Interests
Tumor Acidosis: Dr. Pagel has pioneered the development and application of acidoCEST MRI, which uses Chemical Exchange Saturation Transfer (CEST) to measure the extracellular pH (pHe) in a solid tumor. He has translated acidoCEST MRI to the radiology clinic. He has also developed PET/MRI co-agents and simultaneous PET/MRI methods that can measure tumor pHe. He is currently investigating MR Fingerprinting as another method for measuring tumor pHe. These tumor pHe measurements are used to improve cancer diagnoses, and to evaluate treatments that directly inhibit glycolysis; treatments that more generally reduce metabolism; treatments that are activated in acidic tumors; and pre-treatments that reduce acidosis and improve immunotherapy.
Tumor Hypoxia: The CAMEL group has optimized Oxygen Enhanced (OE) MSOT that measures oxygen saturation (%sO 2 and ΔsO 2 ) that are biomarkers of vascular hypoxia. We are performing a clinical MSOT study that detects hypoxic, metastatic lymph nodes. More recently, Dr. Pagel has been developing OE-EPR (Electron Paramagnetic Resonance) imaging that can measure oxygen pressure (pO 2 ) in the tumor microenvironment. The CAMEL group has combined OE MSOT with DCE MSOT, and is currently combining OE-EPR with DCE EPR, to provide a single scan session that can measure multiple biomarkers of the tumor vasculature. These hypoxia imaging studies are used to evaluate radiotherapy and radiosensitizers, and also assess pre-treatments that reduce hypoxia to improve tumor control with immunotherapy.
Tumor Vascular Perfusion: The CAMEL Group has invented new methods that analyze Dynamic Contrast Enhanced (DCE) MRI that can measure tumor vascular perfusion (RK rans and k ep ). More specifically, our group has developed the Linear Reference Region Model that avoids the need for an Arterial Input Function, relaxes requirements for fat temporal resolution, and improves precision. In addition, our group has developed DCE MSOT that can measure tumor vascular perfusion, and we are developing a similar DCE EPR method. Measurements of vascular perfusion are used to evaluate vascular disrupting agents and radiotherapies. Also, our DCE imaging methods are combined with our methods for imaging tumor hypoxia, and therefore apply to studies of radiotherapy and immunotherapy.
Enzyme Activity: Dr. Pagel pioneered the development of catalyCEST MRI that can detect enzyme activities within in vivo tumor models. More recently, CAMEL is developing MSOT contrast agents that can detect enzyme activities, which can also be used to improve tumor detection during surgery.
Education & Training
Degree-Granting Education
1993 | University of California, Berkeley, CA, USA, PHD, Chemistry |
1988 | Washington University, St. Louis, MO, USA, BA, Biology |
1988 | Washington University, St. Louis, MO, USA, BA, Chemistry |
Experience & Service
Academic Appointments
Professor, Department of Medical Imaging, Biomedical Engineering, and Chemistry & Biochemistry, University of Arizona, Tucson, AZ, 2016 - 2017
Associate Professor, Department of Medical Imaging, Biomedical Engineering and Chemistry & Biochemistry, University of Arizona, Tucson, AZ, 2008 - 2016
Administrative Appointments/Responsibilities
Program Director, Pathway to Systems Imaging, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Honors & Awards
2021 | 2021 Most Cited Publication, Journal of Magnetic Resonance Imaging |
2021 | 2021 Fellow, World Molecular Imaging Society, World Molecular Imaging Society |
2020 | Most downloaded publication in NMR in Biomedicine (DOI: 10.1002/nbm.3943) |
2020 | 2020 Radiology: Imaging Cancer Editor's Recognition Award with Distinction |
2019 | Faculty Excellence Award, The University of Texas at MD Anderson Cancer Center |
2018 | Dallas Fort Worth Living Legend Professorship Endowed Chair |
2017 | Best Clinical Paper Award, Molecular Imaging and Biology |
2012 | Arizona Engineering Faculty Fellow, University of Arizona |
2010 | Sydney E. Salmon Distinguished Junior Investigator Award, Arizona Cancer Center |
2010 | Distinguished Reviewer, Magnetic Resonance in Medicine |
2006 | Case School of Engineering Graduate Teaching Award, Case Western Reserve University |
2005 | Young Investigator Award, Contrast Media Research 2005 Symposium |
2004 | Case UCITE Learning Fellow, Case Western Reserve University |
2003 | Early Career Recognition Award, Pharmacia Corp., St. Louis, MO |
1994 | Staff Award, Department of Chemistry, Indiana University |
1988 | John C. Sowden Memorial Prize, Department of Chemistry, Washington University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep 13(1):1171, 2023. e-Pub 2023. PMID: 36670144.
- Zhou J, Zaiss M, Knutsson L, Sun PZ, Ahn SS, Aime S, Bachert P, Blakeley JO, Cai K, Chappell MA, Chen M, Gochberg DF, Goerke S, Heo HY, Jiang S, Jin T, Kim SG, Laterra J, Paech D, Pagel MD, Park JE, Reddy R, Sakata A, Sartoretti-Schefer S, Sherry AD, Smith SA, Stanisz GJ, Sundgren PC, Togao O, Vandsburger M, Wen Z, Wu Y, Zhang Y, Zhu W, Zu Z, van Zijl PCM. Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors. Magn Reson Med 88(2):546-574, 2022. e-Pub 2022. PMID: 35452155.
- Pollard AC, Paolillo V, Radaram B, Qureshy S, Li L, Tapati M, Wang L, Uddin MdN, Wood CG, Karam JA, Pagel MD, Piwnica-Worms D, Millward SW, Fowlkes NW, Norton W, Engel BJ, Pisaneschi F, Zacharias NM. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[ 18 F]Fluoroglutamine. Mol Imaging Biol 24(6):959-972, 2022. PMID: 35732988.
- Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GM. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging 56(6):1901-1909, 2022. e-Pub 2022. PMID: 35499264.
- Pollard AC, de la Cerda J, Schuler FW, Pollard TR, Kotrotsou A, Pisaneschi F, Pagel MD. Radiometal-Based PET/MRI Contrast Agents for Sensing Tumor Extracellular pH. Biosensors (Basel) 12(2), 2022. e-Pub 2022. PMID: 35200394.
- Kombala CJ, Lokugama SD, Kotrotsou A, Li T, Pollard AC, Pagel MD. Simultaneous Evaluations of pH and Enzyme Activity with a CEST MRI Contrast Agent. ACS Sens 6(12):4535-4544. e-Pub 2021. PMID: 34856102.
- Kombala CJ, Kotrotsou A, Schuler FW, de la Cerda J, Ma JC, Zhang S, Pagel MD. Development of a Nanoscale Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Contrast Agent That Measures pH. ACS Nano 15(12):20678-20688. e-Pub 2021. PMID: 34870957.
- Miller JS, Paulsen SJ, Pan CS, Long J, Grigoryan B, Pagel MD, Micham TM, Sazer DW, Janson KD, Harlan CJ, Bouchard RR. Projection-based stereolithography for direct 3D printing of heterogeneous ultrasound phantoms. PLOS ONE 16(12):e0260737, 2021. PMID: 34882719.
- Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Musall BC, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang KP, Ma J, Pagel MD. Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study. Radiol Imaging Cancer 3(5):e200155, 2021. PMID: 34477453.
- Zhou Z, Jain P, Lu Y, Macapinlac H, Wang ML, Son JB, Pagel MD, Xu G, Ma J. Computer-aided detection of mantle cell lymphoma on 18F-FDG PET/CT using a deep learning convolutional neural network. Am J Nucl Med Mol Imaging 11(4):260-270, 2021. e-Pub 2021. PMID: 34513279.
- Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional Tumor Volumes by Fast DCE-MRI for Predicting Neoadjuvant Systemic Therapy Response of Triple-Negative Breast Cancer. J Magn Reson Imaging 54(1):251-260, 2021. e-Pub 2021. PMID: 33586845.
- Lombardi AF, Wong JH, High R, Ma Y, Jerban S, Tang Q, Du J, Frost P, Pagel MD, Chang EY. AcidoCEST MRI evaluates the bone microenvironment in multiple myeloma. Mol Imaging Biol 23(6):865-873. e-Pub 2021. PMID: 33939066.
- Qayyum A, Bhosale P, Aslam R, Avritscher R, Ma J, Pagel MD, Sun J, Mohamed Y, Rashid A, Beretta L, Kaseb AO. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY) 46(3):1008-1015, 2021. e-Pub 2020. PMID: 32974761.
- Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185(1):1-12, 2021. e-Pub 2020. PMID: 32920733.
- Zhou Z, Sanders JW, Johnson JM, Guile-Monroe M, Chen M, Briere TM, Wang Y, Son JB, Pagel MD, Ma J, Li J. MetNet: Computer-aided segmentation of brain metastases in post-contrast T1-weighted magnetic resonance imaging. Radiother oncol 153:189-196, 2020. e-Pub 2020. PMID: 32937104.
- Sanders JW, Lewis GD, Thames HD, Kudchadker RJ, Venkatesan AM, Bruno TL, Ma J, Pagel MD, Frank SJ. Machine segmentation of pelvic anatomy in MRI-assisted radiosurgery (MARS) for prostate cancer brachytherapy. Int J Radiat Oncol Biol Phys 108(5):1292-1303. e-Pub 2020. PMID: 32634543.
- Harlan CJ, Xu Z, Michel KA, Walker CM, Lokugama SD, Martinez GV, Pagel MD, Bankson JA. Technical Note: A deuterated 13 C-urea reference for clinical multiparametric MRI prostate cancer studies including hyperpolarized pyruvate. Med Phys 47(7):2931-2936, 2020. e-Pub 2020. PMID: 32286689.
- Le Roux LG, Qiu X, Jacobsen MC, Pagel MD, Gammon ST, Piwnica-Worms DR, Schellingerhout D. Axonal Transport as an In Vivo Biomarker for Retinal Neuropathy. Cells 9(5):1298, 2020. e-Pub 2020. PMID: 32456061.
- Dutta P, Pando SC, Mascaro M, Riquelme E, Zoltan M, Zacharias NM, Gammon ST, Piwnica-Worms D, Pagel MD, Sen S, Maitra A, Shams S, McAllister F, Bhattacharya PK. Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy. Int J Mol Sci 21(10):3722, 2020. e-Pub 2020. PMID: 32466260.
- Zhou Z, Sanders JW, Johnson JM, Gule-Monroe MK, Chen MM, Briere TM, Wang Y, Son JB, Pagel MD, Li J, Ma J. Computer-aided Detection of Brain Metastases in T1-weighted MRI for Stereotactic Radiosurgery Using Deep Learning Single-Shot Detectors. Radiology 295(2):407-415. e-Pub 2020. PMID: 32181729.
- Zaibaq NG, Pollard AC, Collins MJ, Pisaneschi F, Pagel MD, Wilson LJ. Evaluation of the Biodistribution of Serinolamide-Derivatized C60 Fullerene. Nanomaterials (Basel) 10(1):143, 2020. e-Pub 2020. PMID: 31941058.
- High RA, Randtke EA, Jones KM, Lindeman LR, Ma JC, Zhang S, Le Roux LG, Pagel MD. Extracellular acidosis differentiates pancreatitis and pancreatic cancer in mouse models using acidoCEST MRI. Neoplasia 21(11):1085-1090, 2019. e-Pub 2019. PMID: 31734629.
- Goldenberg JM, Berthusen AJ, Cárdenas-Rodríguez J, Pagel MD. Differentiation of Myositis-Induced Models of Bacterial Infection and Inflammation with T2-Weighted, CEST, and DCE-MRI. Tomography 5(3):283-291, 2019. PMID: 31572789.
- Lindeman LR, Jones KM, High RA, Howison CM, Shubitz LF, Pagel MD. Differentiating lung cancer and infection based on measurements of extracellular pH with acidoCEST MRI. Sci Rep 9(1):13002, 2019. e-Pub 2019. PMID: 31506562.
- Minhas AS, Sharkey J, Randtke EA, Murray P, Wilm B, Pagel MD, Poptani H. Measuring Kidney Perfusion, pH, and Renal Clearance Consecutively Using MRI and Multispectral Optoacoustic Tomography. Mol Imaging Biol 22(3):494-503. e-Pub 2019. PMID: 31529408.
- Shi S, Wen X, Li T, Wen X, Cao Q, Liu X, Liu Y, Pagel MD, Li C. Thermosensitive Biodegradable Copper Sulfide Nanoparticles for Real-Time Multispectral Optoacoustic Tomography. ACS Appl Bio Mater 2(8):3203-3211, 2019. e-Pub 2019. PMID: 33907729.
- Sanders JW, Fletcher JR, Frank SJ, Liu HL, Johnson JM, Zhou Z, Chen HS, Venkatesan AM, Kudchadker RJ, Pagel MD, Ma J. Deep learning application engine (DLAE): Development and integration of deep learning algorithms in medical imaging. SoftwareX 10, 2019. e-Pub 2019. PMID: 34113706.
- Goldenberg JM, Cárdenas-Rodríguez J , Pagel MD. Machine learning improves classification of preclinical models of pancreatic cancer with chemical exchange saturation transfer MRI. Magn Reson Med 81(1):594-601, 2019. PMID: 30277270.
- Som A, Raliya R, Paranandi K, High RA, Reed N, Beeman SC, Brandenburg M, Sudlow G, Prior JL, Akers W, Mah-Som AY, Habimana-Griffin L, Garbow J, Ippolito JE, Pagel MD, Biswas P, Achilefu S. Calcium carbonate nanoparticles stimulate tumor metabolic reprogramming and modulate tumor metastasis. Nanomedicine (Lond) 14(2):169-182, 2019. e-Pub 2018. PMID: 30730790.
- Li X, Shepard HM, Cowell JA, Zhao C, Osgood RJ, Rosengren S, Blouw B, Garrovillo SA, Pagel MD, Whatcott CJ, Han H, Von Hoff DD, Taverna DM, LaBarre MJ, Maneval DC, Thompson CB. Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression. Clin Cancer Res 24(19):4798-4807, 2018. e-Pub 2018. PMID: 30084839.
- Goldenberg JM, Pagel MD, Cárdenas-Rodríguez J. Characterization of D-maltose as a T2-exchange contrast agent for dynamic contrast enhanced MRI. Magn Reson Med 80(3):1158-1164, 2018. PMID: 2936940.
- Goldenberg JM, Pagel MD, Cárdenas-Rodríguez J. Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI. Magn Reson Med 80(3):1158-1164, 2018. e-Pub 2018. PMID: 29369407.
- Hupple CW, Morscher S, Burton NC, Pagel MD, McNally LR, Cárdenas-Rodríguez J. A light-fluence-independent method for the quantitative analysis of dynamic contrast-enhanced multispectral optoacoustic tomography (DCE MSOT). Photoacoustics 10:54-64, 2018. e-Pub 2018. PMID: 29988890.
- Lindeman LR, Randtke EA, High RA, Jones KM, Howison CM, Pagel MD. A comparison of exogenous and endogenous CEST MRI methods for evaluating in vivo pH. Magn Reson Med 79(5):2766-2772, 2018. e-Pub 2017. PMID: 29024066.
- Sinharay S, Randtke EA, Howison CM, Ignatenko NA, Pagel MD. Detection of Enzyme Activity and Inhibition during Studies in Solution, In Vitro and In Vivo with CatalyCEST MRI. Mol Imaging Biol 20(2):240-248, 2018. PMID: 28726131.
- Jones KM, Pagel MD, Cárdenas-Rodríguez J. Linearization improves the repeatability of quantitative dynamic contrast-enhanced MRI. Magn Reson Imaging 47:16-24, 2018. e-Pub 2017. PMID: 29155024.
- Goldenberg JM, Cardenas-Rodriguez J, Pagel MD. Preliminary results that assess metformin treatment in a preclinical model of pancreatic cancer using simultaneous [18F]FDG PET and acidoCEST MRI. Mol Imaging Biol 20(4):575-583, 2018. PMID: 29374343.
- Kobes J, Georgiev GI, Louis AV, Calderon IA, Yoshimaru ES, Klemm LM, Cromey D, Khalpey Z, Pagel MD. A comparison of iron oxide particles and silica particles for tracking organ recellularization. Mol Imaging 17, 2018. PMID: 30039729.
- Jones KM, Stuehm CA, Hsu CC, Kuo PH, Pagel MD, Randtke EA. Imaging Lung Cancer by Using Chemical Exchange Saturation Transfer MRI With Retrospective Respiration Gating. Tomography 3(4):201-210, 2017. PMID: 29479563.
- Randtke EA, Granados JC, Howison CM, Pagel MD, Cárdenas-Rodríguez J. Multislice CEST MRI improves the spatial assessment of tumor pH. Magn Reson Med 78(1):97-106, 2017. e-Pub 2016. PMID: 27465207.
- Sinharay S, Howison CM, Baker AF, Pagel MD. Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent. NMR Biomed 30(7):10.1002/nbm.3721, 2017. e-Pub 2017. PMID: 28370884.
- Sinharay S, Randtke EA, Jones KM, Howison CM, Chambers SK, Kobayashi H, Pagel MD. Noninvasive detection of enzyme activity in tumor models of human ovarian cancer using catalyCEST MRI. Magn Reson Med 77(5):2005-2014, 2017. e-Pub 2016. PMID: 27221386.
- Daryaei I, Jones KM, Pagel MD. Detection of DT-diaphorase Enzyme with a ParaCEST MRI Contrast Agent. Chemistry 23(27):6514-6517, 2017. e-Pub 2017. PMID: 28370655.
- Daryaei I, Randtke EA, Pagel MD. A biomarker-responsive T2ex MRI contrast agent. Magn Reson Med 77(4):1665-1670, 2017. e-Pub 2016. PMID: 27090199.
- Daryaei I, Pagel MD. Double agents and secret agents: the emerging fields of exogenous chemical exchange saturation transfer and T2-exchange magnetic resonance imaging contrast agents for molecular imaging. Res Rep Nucl Med 5:19-32, 2015. PMID: 27747191.
- Sen A, Kingsley CV, de la Cerda J, Schuler FW, Mohammed ASR, Pagel MD, Brock KK. Towards assessment of histopathology correlation with multiple imaging modalities: A pilot study using a visible mouse. Proc SPIE Med Imaging 2020:11317:113172B.
Other Articles
- Sen A, Troncoso P, Venkatesan A, Pagel MD, Nijkamp JA, He Y, Lesage AC, Woodland M, Brock KK Correlation of in-vivo imaging with histopathology: A review. Eur J Radiol 144:109964, 2021. PMID: 34619617.
- Corbin BA, Pollard AC, Allen MJ, Pagel MD Summary of Imaging in 2020: Visualizing the Future of Healthcare with MR Imaging. Mol Imaging Biol 21(2):193-199, 2019. PMID: 30680525.
- Goldenberg JM, Pagel MD Assessments of tumor metabolism with CEST MRI. NMR Biomed 32(10):e3943. PMID: 29938857.
- Jones KM, Pollard AC, Pagel MD Clinical applications of chemical exchange saturation transfer (CEST) MRI. J Magn Reson Imaging 47(1):11-27, 2018. PMID: 28792646.
- Nickels ML, Pagel MD Managers of Molecular Imaging Laboratories (MOMIL) interest group. Molec Biol Imaging 19(3):332-335, 2017. PMID: 28299547.
- Akhenblit PJ, Pagel MD Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy. J Cancer Sci Ther 8(1):20-29, 2016. PMID: 26962408.
- Sinharay S, Pagel MD Advances in magnetic resonance imaging contrast agents for biomarker detection. Annu Rev Anal Chem 9(1):95-115, 2016. PMID: 27049630.
- Chen LQ, Pagel MD Evaluating pH in the extracellular tumor microenvironment using CEST MRI and other imaging methods. Adv Radiol 206405, 2015. PMID: 27761517.
Editorials
- Pagel MD. Recommendations for Reviewers of Biomedical Imaging Grant Applications. Mol Imaging Biol 21(4):612-619, 2019. PMID: 30460624.
- Pagel MD. Science to practice: can photoacoustic imaging be used to monitor tumor oxygenation and the effects of antivascular chemotherapies?. Radiology 275(1):1-2, 2015. PMID: 25799329.
- Pagel MD. The hope and hype of multimodality imaging contrast agents. Nanomedicine (Lond) 6(6):945-8, 2011. PMID: 21955073.
- Pagel MD. Responsive paramagnetic chemical exchange saturation transfer MRI contrast agents. Imaging Med 3(4):377-380, 2011. PMID: 30854026.
Abstracts
- Chin R, Pagel MD. Priming Tumors Using pH Sensitizers Potentiates the Anti-tumor T Cell Response Induced by Immune Checkpoint Blockade Therapy: Valuations of Tumor Acidosis and Hypoxia with AcidoCEST MRI and EPR Imaging. 2022 CSI Spring Retreat, 2022.
- Thompson E, Pagel MD. Alkaline Embolization In Vivo: Multi-Modal Feasibility Study using Computed Tomography, Fluoroscopy, and Mass Spectrometry Imaging. 2022 CSI Spring Retreat, 2022.
- Thompson E, Pagel MD. Quantitative Image Guidance In Vivo: Dual-Energy CT for Thermochemical Ablation. 2022 CSI Spring Retreat, 2022.
Book Chapters
- Daryaei I, Pagel MD. Responsive paraCEST MRI Contrast Agents and their Biomedical Applications. In: Chemical Exchange Saturation Transfer Imaging: Advances and Applications, 2017.
- Sinharay S, Pagel MD. Advances in Magnetic Resonance Imaging Contrast Agents for Biomarker Detection. In: Annual Reviews in Analytical Chemistry, 2016.
- Sheth VR, Pagel MD. CEST & PARACEST MRI contrast agents for imaging cancer biomarkers. In: Molecular Imaging Probes for Cancer Research, 2012.
- Pagel MD, Basilion JP. Non-invasive imaging of genes and gene expression with magnetic resonance imaging and magnetic resonance spectroscopy. In: In: Molecular Imaging with Reporter Genes. Cambridge University Press, 2011.
Grant & Contract Support
Title: | Assessments of Tumor Perfusion with Dynamic Contrast Enhanced Multispectral Optoacoustic Tomography |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Principal Investigator |
Title: | Measuring Tumor Acidosis with PET/MRI Contrast Agents |
Funding Source: | NIH/NIBIB |
Role: | Principal Investigator |
Title: | Development and Dissemination of Clinical CEST MRI Acquisition and Analysis Methods for Cancer Imaging Applications |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Institutional Start-up Funding |
Funding Source: | The University of Texas MD Anderson Cancer Center |
Role: | Principal Investigator |
Title: | Cancer Center Support Grant - Radiation Oncology and Cancer Imaging Research Program |
Funding Source: | NIH/NCI |
Role: | Co-Program Leader |
Title: | Exploiting Melanin Synthesis to Improve Tumor Detection with Multispectral Optoacoustic Tomography and Optical Guided Surgery |
Funding Source: | NIH/NIBIB |
Role: | Principal Investigator |
Title: | Investigation of the Role of Epithelial-mesenchymal Plasticity in Renal Cell Carcinoma |
Funding Source: | NIH/NCI |
Role: | Collaborator |
Title: | Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology |
Funding Source: | NIH/NCI |
Role: | Mentor |
Title: | Novel Multispectral Optoacoustic Tomography Contrast Agents for Evaluation of Early Response to Radiation Therapy |
Funding Source: | NIH/NIBIB |
Role: | Co-Principal Investigator |
Title: | Evaluation of AcidoCEST-MRI/64Cu-pHLIP-PET in Various Cancer Models |
Funding Source: | F. Hoffmann-La Roche Ltd |
Role: | Principal Investigator |
Title: | Quantitative Measurements of Tumor Perfusion and Oxygenation with Multispectral Optoacoustic Tomography |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Transforming the Standard of Care: A Personalized Approach for Patients with Cancer Metastatic to the Brain |
Funding Source: | Brockman Foundation |
Role: | Co-Investigator |